U.S. HMC SERIES FUND LP - SERIES VIII records an exempt offering totaling $13,250,000, with $100,000 sold and eight investors listed. The figures give investors the fund’s stated fundraising scale, reported amount sold, participation count and $15,000 allocation for organizational and operating expenses.
Key Highlights
- The fund lists $15,000 for organizational and operating expenses.
- The offering record identifies eight investors.
- Lind Global Fund III LP is reported with 5.65% ownership of Dare Bioscience, representing 1,094,890 common shares.
U.S. HMC SERIES FUND LP - SERIES VIII records an exempt offering totaling $13,250,000, with $100,000 shown as sold. The fund identifies itself as a Delaware Limited Liability company and a Venture Capital pooled Investment fund.
$13.25M Offering and Fund Structure
Eight investors are identified, while $15,000 is allocated to cover organizational and operating expenses. George G. Chen is identified as managing member for U.S. HMC SERIES FUND LP - SERIES VIII, with the record dated 1 September 2026. The record includes a decline-to-disclose entry and identifies the offering under exemptions marked 06b, 3C and 3C.1. A separate ownership record names Lind Global Fund III LP as reporting 5.65% ownership of Dare Bioscience, Inc (NASDAQ: DARE). consisting of 1,094,890 shares of common stock (1.09 million), 1,094,890 Series A Warrants and 1,094,890 Series B Warrants.
FAQs
Q: What is the U.S. HMC Series Fund LP Series VIII offering size?
A: U.S. HMC Series Fund LP - Series VIII lists an exempt offering totaling $13,250,000. The record shows $100,000 sold and an indefinite offering period.
Q: How many investors are listed for the U.S. HMC Series VIII offering?
A: The U.S. HMC Series VIII offering record identifies eight investors. It also allocates $15,000 to cover organizational and operating expenses for the fund.
Q: What ownership did Lind Global Fund III report in Dare Bioscience?
A: Lind Global Fund III LP reported 5.65% ownership of Dare Bioscience, Inc. The position includes 1,094,890 common shares and the same number of Series A and Series B Warrants.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.